Group 1 - The company operates in the medical products, medical services, and health industry sectors [7] - The company's performance has been negatively impacted by a decrease in hospital engineering projects due to industry conditions, leading to a reduction in medical engineering service revenue [7] - The company has increased its provision for bad debts due to lower-than-expected hospital project payments [7] Group 2 - The export business of medical consumables has faced challenges due to international circumstances, resulting in decreased revenue and increased costs, which have led to a decline in gross profit margin [7] - Currency fluctuations have contributed to an increase in exchange losses recognized by the company [7] - The company has also increased its asset impairment provisions during the reporting period [7] Group 3 - Historical net profit and non-recurring profit growth rates show significant fluctuations, with a notable decline in 2022 and projections for 2023 indicating continued challenges [10] - The company's net profit and non-recurring profit have shown negative trends in quarterly changes, indicating ongoing financial difficulties [10]

公告中解释本次业绩变动的原因为： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，尚荣医疗发布业绩预告，预计2025年全年扣非后净利润亏损1.36亿元至1.86亿元。 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。 1、受行业经营环境影响导致公司承接的医院工程项目减少,相应的公司医疗工程服务收入减少;2、医院 工程项目回款不及预期,本期计提的应收账款坏账准备增加;3、医疗耗材出口业务受国际形势的影响,出 口业务收入减少、成本增加导致毛利率下降;4、汇率波动导致公司确认 ...

证券之星消息，尚荣医疗发布业绩预告，预计2025年全年归属净利润亏损1.2亿元至1.7亿元。 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 1、受行业经营环境影响导致公司承接的医院工程项目减少,相应的公司医疗工程服务收入减少;2、医院 工程项目回款不及预期,本期计提的应收账款坏账准备增加;3、医疗耗材出口业务受国际形势的影响,出 口业务收入减少、成本增加导致毛利率下降;4、汇率波动导致公司确认的汇兑 ...

尚荣医疗公告，预计2025年度归属于上市公司股东的净利润为-1.7亿元至-1.2亿元，上年同期为2228.2万 元。扣除非经常性损益后的净利润为-1.86亿元至-1.36亿元，上年同期为1165.81万元。基本每股收益 为-0.2011元/股至-0.142元/股，上年同期为0.0264元/股。 ...

证券代码：002551 证券简称：尚荣医疗 公告编号： 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 2026-001 深圳市尚荣医疗股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 4、汇率波动导致公司确认的汇兑损失增加； 5、公司本期计提资产减值准备增加。 四、风险提示 2、医院工程项目回款不及预期，本期计提的应收账款坏账准备增加； 3、医疗耗材出口业务受国际形势的影响，出口业务收入减少、成本增加导致毛利率 下降； | 项 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -17,000.00 | ～ | -12,000.00 | 2,228.20 | | 扣除非经常性损益后的净利润 | -18,619.26 | ～ | -13,619.26 | 1,165.81 | | 基本每股收益（元/股 ...

尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。尚荣医疗（002551）主营业务：医疗产品生产销售、医疗服务、健康 产业运营等。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 证 ...

1月19日的资金流向数据方面，主力资金净流出213.7万元，占总成交额5.71%，游资资金净流出4.96万 元，占总成交额0.13%，散户资金净流入218.66万元，占总成交额5.84%。 证券之星消息，截至2026年1月19日收盘，尚荣医疗(002551)报收于3.84元，上涨1.32%，换手率1.6%， 成交量9.79万手，成交额3743.03万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降2 ...

Group 1 - The core point of the article highlights that Shangrong Medical (002551) experienced a decline in stock price, closing at 3.79 yuan on January 16, 2026, with a drop of 1.56% and a turnover rate of 2.2% [1] - The company reported a significant decrease in its main revenue for the first three quarters of 2025, amounting to 754 million yuan, which represents a year-on-year decline of 24.85% [2] - The net profit attributable to the parent company for the same period was -35.13 million yuan, showing a drastic year-on-year decrease of 338.5% [2] Group 2 - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, reflecting a year-on-year decline of 39.25% [2] - The single-quarter net profit attributable to the parent company was -27.37 million yuan, indicating a year-on-year decrease of 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income reported at 10.20 million yuan and financial expenses at -3.79 million yuan, while the gross profit margin is 14.35% [2]

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges for the company moving forward [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The non-recurring net profit was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The single-quarter non-recurring net profit was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stood at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin was reported at 14.35% [2]. Market Activity - As of January 14, 2026, Shangrong Medical's stock closed at 3.93 yuan, with an increase of 0.26% [1]. - The turnover rate was 3.92%, with a trading volume of 239,800 hands and a transaction value of 94.23 million yuan [1]. - On January 14, the net inflow of main funds was 3.77 million yuan, accounting for 4.0% of the total transaction value, while retail funds saw a net inflow of 3.78 million yuan, also representing 4.01% of the total [1].

Core Viewpoint - The stock of Shangrong Medical (002551) has experienced a decline, with significant net outflows from major and retail investors, indicating a bearish sentiment in the market [1][2]. Group 1: Stock Performance - As of January 7, 2026, Shangrong Medical's stock closed at 3.75 yuan, down 3.1% with a turnover rate of 3.79% and a trading volume of 231,600 hands, resulting in a transaction amount of 87.66 million yuan [1]. - In the five days leading up to January 7, the stock showed fluctuations, with a peak closing price of 3.87 yuan on January 6, reflecting a 2.11% increase, followed by a decline on January 7 [2]. Group 2: Fund Flow Analysis - On January 7, 2026, the net outflow of major funds was 604.43 million yuan, accounting for 6.89% of the total transaction amount, while retail investors saw a net inflow of 761.79 million yuan, representing 8.69% of the total [1][2]. - Over the past five days, major funds fluctuated significantly, with a net inflow of 974.64 million yuan on January 5, followed by a net outflow on subsequent days [2]. Group 3: Company Financials and Industry Comparison - Shangrong Medical's total market capitalization is 3.171 billion yuan, with a net asset value of 2.73 billion yuan, and a net profit of -35.13 million yuan, indicating poor financial performance compared to the industry averages [3]. - The company's gross margin stands at 14.35%, significantly lower than the industry average of 51.02%, and its net profit margin is -4.6%, compared to the industry average of 9.59% [3]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85%, with a net profit decline of 338.5% [3].